Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» raludotatug deruxtecan
raludotatug deruxtecan
Daiichi Sankyo and Merck dose first subject in ovarian cancer trial
Clinical Trials Arena
Thu, 04/4/24 - 10:53 am
Daiichi Sankyo
Merck
ovarian cancer
clinical trials
raludotatug deruxtecan
R-DXd